Khalid Mezzi

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

Meletios Α. Dimopoulos, David S. Siegel, Darrell White et al. · Blood · 2018 · 42 citations · Full text

Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare

Nicole Gormley, Lola A. Fashoyin‐Aje, Trevan Locke et al. · Blood Cancer Discovery · 2021 · 39 citations · Full text

Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study

Ajai Chari, Khalid Mezzi, Shao Zhu et al. · BMC Cancer · 2016 · 35 citations · Full text

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

Thierry Façon, Rubén Niesvizky, María‐Victoria Mateos et al. · Blood Advances · 2020 · 31 citations · Full text

Hematological Malignancy, Translational Medicine, Carfilzomib-based Regimens +15

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies

Andrzej Jakubowiak, Jeanne M. DeCara, Khalid Mezzi · Hematology · 2017 · 20 citations · Full text